Skip to main content
Shenzhen Bioeasy Biotechnology Co., Ltd. logo

Shenzhen Bioeasy Biotechnology Co., Ltd. — Investor Relations & Filings

Ticker · 300942 ISIN · CNE100004C78 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2026-04-26 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300942

About Shenzhen Bioeasy Biotechnology Co., Ltd.

https://www.bioeasy.com

Shenzhen Bioeasy Biotechnology Co., Ltd. specializes in the development, production, and marketing of rapid testing solutions for food safety, clinical diagnosis, and animal health. The company provides a comprehensive portfolio of diagnostic products, including rapid test strips, enzyme-linked immunosorbent assay (ELISA) kits, and automated detection instruments. Its core focus areas include the detection of antibiotic residues, mycotoxins, pesticides, and foodborne pathogens in dairy, meat, seafood, and grain products. In the clinical sector, Bioeasy offers point-of-care testing (POCT) solutions for infectious diseases and chronic conditions. The company emphasizes research and development to deliver high-sensitivity, user-friendly diagnostic tools that meet international quality standards. Its products are utilized by food producers, regulatory agencies, and healthcare providers to ensure safety and quality control across the global supply chain.

Recent filings

Filing Released Lang Actions
东兴证券股份有限公司关于深圳市易瑞生物技术股份有限公司2025年度现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "现场检查报告" (On-site Inspection Report) for the year 2025 concerning Shenzhen Easy Diagnosis Biotechnology Co., Ltd., prepared by Dongxing Securities Co., Ltd. It details the inspection of company governance, internal controls, information disclosure, use of raised funds, and performance issues. The content includes detailed findings from the inspection, including financial performance analysis and compliance with regulations. It is not a full annual report (10-K), nor a simple announcement or certification. It is a standalone audit or inspection report focusing on regulatory compliance and internal controls, consistent with an Audit Report / Information (AR). The document length is over 5,000 characters and contains substantive content, not just an announcement or certification. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2025
2026-04-26 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Yirui Biotechnology Co., Ltd. regarding a change in accounting policies due to a new interpretation of accounting standards issued by the Ministry of Finance of China. It specifies the effective date of the new policy and states that the change does not have a material impact on the company's financials. The document is relatively short (1065 characters) and serves as a formal disclosure of the accounting policy change rather than a full financial report or audit report. It does not contain detailed financial statements or audit opinions. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2026-04-26 Chinese
董事会审计委员会对会计师事务所2025年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee evaluating the performance and supervision of the accounting firm for the fiscal year 2025. It discusses the audit firm's qualifications, the audit process, communication with the audit committee, and the issuance of an unqualified audit opinion on the company's 2025 financial statements. The document does not contain the full annual report or the financial statements themselves but is a detailed report on the audit firm's performance and the audit committee's oversight. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and related evaluations, excluding the full Annual Report (10-K). The document length is 2250 characters, which is relatively short but contains substantive content about the audit process and results, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2025
2026-04-26 Chinese
东兴证券股份有限公司关于深圳市易瑞生物技术股份有限公司2025年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2025年度持续督导跟踪报告" which translates to "2025 Annual Continuous Supervision Follow-up Report" by the sponsor (东兴证券股份有限公司) for the company 深圳市易瑞生物技术股份有限公司. It details the sponsor's supervision activities, review of company disclosures, governance, fundraising supervision, and issues found during the reporting period. It includes detailed descriptions of the sponsor's work, findings, and measures taken, as well as changes in sponsor representatives. The document is not a full annual report (10-K), nor an earnings release or audit report. It is a regulatory supervision follow-up report related to the sponsor's ongoing monitoring duties. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance and supervision report that does not fit other specific categories and is not a direct financial report or announcement of voting or capital changes.
2026-04-26 Chinese
关于2025年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Yirui Biotechnology Co., Ltd. regarding the asset impairment provision for the fiscal year 2025. It details the reasons, amounts, accounting standards applied, and the impact on the company's financials. The document is relatively short (2638 characters) and is structured as a formal announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it focuses on a specific accounting event (asset impairment provision) and its impact, which is typical of a Regulatory Filing (RNS) as it is a regulatory disclosure about a specific accounting matter. There is no indication that this is a full audit report or a management discussion and analysis document. Therefore, the best classification is Regulatory Filings (RNS).
2026-04-26 Chinese
第三届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 15th meeting of the third board of directors of Shenzhen Yirui Biotechnology Co., Ltd. It includes approvals of various reports such as the 2025 Annual Board Work Report, 2025 Annual General Manager Work Report, 2025 Annual Report and its summary, profit distribution plan, fundraising usage report, internal control self-evaluation report, and the 2026 first quarter report. It also covers decisions on remuneration, appointment of senior management, and other corporate governance matters. The document is a formal board meeting resolution announcement, not the actual reports themselves. It references that the full reports are available on the official disclosure website (cninfo.com.cn). The document is over 5,000 characters and contains substantive content about board decisions and approvals, but it is not the full annual report or quarterly report itself. It is a board/management information announcement about board meeting resolutions and approvals. Therefore, the appropriate classification is Board/Management Information (MANG).
2026-04-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.